Insiders · NBRV

Daniel Dolan

Officer at Nabriva Therapeutics plc (NBRV) since March 2021

Daniel Dolan has filed 4 insider reports with the SEC since March 2021, as officer at Nabriva Therapeutics plc (NBRV). The latest filing, on August 16, 2022, reports exercise or conversion of a derivative at Nabriva Therapeutics plc (NBRV).

Filings
4
Companies
1
Bought on market
None
Sold on market
None

Companies where Daniel Dolan is an insider

CompanyRoleShares heldBoughtSoldAvg buyPrice nowLast filing
Nabriva Therapeutics plc logo
NBRV
Nabriva Therapeutics plc
Officersince March 2021Aug 16, 2022

Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record.

Every filing

Compare Daniel Dolan with

Questions about Daniel Dolan

What is Daniel Dolan's role at Nabriva Therapeutics plc?
Daniel Dolan reports to the SEC as officer at Nabriva Therapeutics plc (NBRV), according to the latest filing on August 16, 2022.
Has Daniel Dolan bought or sold stock recently?
No open-market purchases or sales by Daniel Dolan are on file. The filings report exercise or conversion of a derivative and grant or award.
How do I get alerts when Daniel Dolan files?
Follow Daniel Dolan on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale.

From SEC Forms 3, 4, 5 and 144 filed by Daniel Dolan (SEC CIK 0001826818). Totals count each trade once, skipping amendments whose original is on file, from Mar 16, 2021 on. View on SEC EDGAR